Abstract:NanomedicineVol. 16, No. 19 EditorialNanomedicine in boron neutron capture therapy for cancer treatment: opportunities, challenges and future perspectivesWei-Jen Chan & Fan-Gang TsengWei-Jen ChanEngineering & System Science, National Tsing Hua University, Hsinchu, 30013, TaiwanSearch for more papers by this author & Fan-Gang Tseng *Author for correspondence: Tel.: +88 603 571 513 134 270; E-mail Address: fangang@ess.nthu.edu.twhttps://orcid.org/0000-0001-7654-6905Engineering & System Science, National Tsing Hua University, Hsinchu, 30013, TaiwanFrontier Research Center on Fundamental & Applied Sciences of Matters, National Tsing Hua University, Hsinchu, 30013, TaiwanResearch Center for Applied Sciences, Academia Sinica, Taipei, 11529, TaiwanSearch for more papers by this authorPublished Online:15 Jul 2021https://doi.org/10.2217/nnm-2021-0082AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: boron neutron capture therapyEPR effectnanomedicinesReferences1. Dymova MA, Taskaev SY, Richter VA, Kuligina EV. Boron neutron capture therapy: current status and future perspectives. Cancer Commun. 40(9), 406–421 (2020).Crossref, Google Scholar2. Franken NA, ten Cate R, Krawczyk PM et al. Comparison of RBE values of high-LET α-particles for the induction of DNA-DSBs, chromosome aberrations and cell reproductive death. Radiat. Oncol. 6, 64 (2011).Crossref, Medline, Google Scholar3. Jing X, Yang F, Shao C et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol. Cancer 18(1), 1–15 (2019).Crossref, Medline, Google Scholar4. Suzuki M. Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era. Int. J. Clin. Oncol. 25(1), 43–50 (2020).Crossref, Medline, Google Scholar5. Hopewell JW, Gorlia T, Pellettieri L, Giusti V, H-Stenstam B, Sköld K. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Appl. Radiat. Isot. 69(12), 1737–1740 (2011).Crossref, Medline, CAS, Google Scholar6. Luderer MJ, De La Puente P, Azab AK. Advancements in tumor targeting strategies for boron neutron capture therapy. Pharm. Res. 32(9), 2824–2836 (2015).Crossref, Medline, CAS, Google Scholar7. Lamba M, Goswami A, Bandyopadhyay A. A periodic development of BPA and BSH based derivatives in boron neutron capture therapy (BNCT). Chem. Comm. 57(7), 827–839 (2021).Crossref, Medline, CAS, Google Scholar8. Malouff TD, Seneviratne DS, Ebner DK et al. Boron neutron capture therapy: a review of clinical applications. Front. Oncol. 11, 351 (2021).Crossref, Google Scholar9. Ichikawa H, Taniguchi E, Fujimoto T, Fukumori Y. Biodistribution of BPA and BSH after single, repeated and simultaneous administrations for neutron-capture therapy of cancer. Appl. Radiat. Isot. 67(7-8), S111–S114 (2009).Crossref, Medline, CAS, Google Scholar10. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268(1), 235–237 (1990).Crossref, Medline, CAS, Google Scholar11. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 21(5), 797–802 (2010).Crossref, Medline, CAS, Google Scholar12. Zhang Q, Liang J, Yun SLJ, Liang K, Yang D, Gu Z. Recent advances in improving tumor-targeted delivery of imaging nanoprobes. Biomater. Sci. 8(15), 4129–4146 (2020).Crossref, Medline, CAS, Google Scholar13. Chan WJ, Cho HL, Goudar V et al. Boron-enriched polyvinyl-alcohol/boric-acid nanoparticles for boron neutron capture therapy. Nanomedicine (Lond.) 16(6), 441–452 (2021).Link, CAS, Google Scholar14. Zhu Y, Lin Y, Zhu YZ, Lu J, Maguire JA, Hosmane NS. Boron drug delivery via encapsulated magnetic nanocomposites: a new approach for BNCT in cancer treatment. J. Nanomater. 2010, 409320 (2010).Crossref, Google Scholar15. Sia J, Szmyd R, Hau E, Gee HE. Molecular mechanisms of radiation-induced cancer cell death: a primer. Front. Cell Dev. Biol. 8, 41 (2020).Crossref, Medline, Google Scholar16. Zhang H, Cheng T, Lai L et al. BN nanospheres functionalized with mesoporous silica for enhancing CpG oligodeoxynucleotide-mediated cancer immunotherapy. Nanoscale 10(30), 14516–14524 (2018).Crossref, Medline, CAS, Google Scholar17. Cioran AM, Musteti AD, Teixidor F et al. Mercaptocarborane-capped gold nanoparticles: electron pools and ion traps with switchable hydrophilicity. J. Am. Chem. Soc. 134(1), 212–221 (2012).Crossref, Medline, CAS, Google Scholar18. Xiong H, Zhou D, Qi Y et al. Doxorubicin-loaded carborane-conjugated polymeric nanoparticles as delivery system for combination cancer therapy. Biomacromolecules 16(12), 3980–3988 (2015).Crossref, Medline, CAS, Google Scholar19. Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J. Control. Rel. 244, 108–121 (2016).Crossref, Medline, CAS, Google Scholar20. Harrington KJ, Mohammadtaghi S, Uster PS et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 7(2), 243–254 (2001).Medline, CAS, Google Scholar21. Moghimi SM, Simberg D. Nanoparticle transport pathways into tumors. J. Nanopart. Res. 20(6), 169–172 (2018).Crossref, Medline, CAS, Google Scholar22. Bürtin F, Mullins CS, Linnebacher M. Mouse models of colorectal cancer: past, present and future perspectives. World J. Gastroenterol. 26(13), 1394 (2020).Crossref, Medline, CAS, Google Scholar23. Mugisho OO, Robilliard LD, Nicholson LF, Graham ES, O'Carroll SJ. Bradykinin receptor-1 activation induces inflammation and increases the permeability of human brain microvascular endothelial cells. Cell Biol. Int. 44(1), 343–351 (2020).Crossref, CAS, Google Scholar24. Tansi FL, Fröbel F, Maduabuchi WO et al. Effect of matrix-modulating enzymes on the cellular uptake of magnetic nanoparticles and on magnetic hyperthermia treatment of pancreatic cancer models in vivo. Nanomaterials 11(2), 438 (2021).Crossref, Medline, CAS, Google Scholar25. Mainetti LE, Rico MJ, Kaufman CD et al. Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models. Oncotarget 11(32), 3048 (2020).Crossref, Medline, Google Scholar26. Chauhan VP, Martin JD, Liu H et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4(1), 2516 (2013).Crossref, Medline, Google Scholar27. Varveris H, Kachris S, Mazonakis M et al. Pegulated liposomal doxorubicin and cisplatin given concurrently with conventional radiotherapy: a Phase I dose-escalation trial for patients with squamous cell carcinoma of head and neck and lung. Oncol. Rep. 12(2), 473–481 (2004).Medline, CAS, Google Scholar28. Liu X, Zhang Y, Wang Y et al. Comprehensive understanding of magnetic hyperthermia for improving antitumor therapeutic efficacy. Theranostics 10(8), 3793 (2020).Crossref, Medline, CAS, Google Scholar29. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 60(16), 4440–4445 (2000).Medline, CAS, Google Scholar30. Kobayashi H, Furusawa A, Rosenberg A, Choyke PL. Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. Int. Immunol. 33(1), 7–15 (2021).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 16, No. 19 Follow us on social media for the latest updates Metrics Downloaded 115 times History Received 1 March 2021 Accepted 28 April 2021 Published online 15 July 2021 Published in print August 2021 Information© 2021 Future Medicine LtdKeywordsboron neutron capture therapyEPR effectnanomedicinesAuthor contributionsWJ Chan and FG Tseng wrote this manuscript. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.Data sharing statementThe authors did not report the original results of a clinical trial or the secondary analysis of clinical trial data.PDF download

Abstract:NanomedicineVol. 16, No. 17 EditorialObstacles impeding the development of nanocarriers for anticancer drugsLingshan Liu & Hongjing DouLingshan Liu https://orcid.org/0000-0002-0176-1464The State Key Laboratory of Metal Matrix Composites, School of Materials Science & Engineering, Shanghai Jiao Tong University, Shanghai 200240, PR ChinaSearch for more papers by this author & Hongjing Dou *Author for correspondence: E-mail Address: hjdou@sjtu.edu.cnhttps://orcid.org/0000-0001-5850-9174The State Key Laboratory of Metal Matrix Composites, School of Materials Science & Engineering, Shanghai Jiao Tong University, Shanghai 200240, PR ChinaSearch for more papers by this authorPublished Online:18 Jun 2021https://doi.org/10.2217/nnm-2021-0101AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: endocytosismononuclear phagocytic systemnanomedicineprotein coronatumor penetrationReferences1. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. doi:10.3322/caac.21660 (2021) (Epub ahead of print).Crossref, Medline, Google Scholar2. Miller KD, Nogueira L, Mariotto AB et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. 69(5), 363–385 (2019).Crossref, Medline, Google Scholar3. Youn YS, Bae YH. Perspectives on the past, present, and future of cancer nanomedicine. Adv. Drug Deliv. Rev. 130, 3–11 (2018).Crossref, Medline, CAS, Google Scholar4. Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. Engl. 53(46), 12320–12364 (2014).Medline, CAS, Google Scholar5. Xing R, Liu K, Jiao T et al. An injectable self-assembling collagen-gold hybrid hydrogel for combinatorial antitumor photothermal/photodynamic therapy. Adv. Mater. 28(19), 3669–3676 (2016).Crossref, Medline, CAS, Google Scholar6. Liu Y, Bhattarai P, Dai Z, Chen X. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem. Soc. Rev. 48(7), 2053–2108 (2019).Crossref, Medline, CAS, Google Scholar7. Karimi M, Ghasemi A, Sahandi Zangabad P et al. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem. Soc. Rev. 45(5), 1457–1501 (2016).Crossref, Medline, CAS, Google Scholar8. Fan W, Yung B, Huang P, Chen X. Nanotechnology for multimodal synergistic cancer therapy. Chem. Rev. 117(22), 13566–13638 (2017).Crossref, Medline, CAS, Google Scholar9. Wilhelm S, Tavares A, Dai QEA. Analysis of nanoparticle delivery to tumors. Nat. Rev. Mater. 1(5), 16014 (2016).Crossref, CAS, Google Scholar10. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17(1), 20–37 (2017).Crossref, Medline, CAS, Google Scholar11. Khawar IA, Kim JH, Kuh HJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. J. Control. Release 201, 78–89 (2015).Crossref, Medline, CAS, Google Scholar12. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 65(1), 71–79 (2013).Crossref, Medline, CAS, Google Scholar13. Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem. Soc. Rev. 42(3), 1147–1235 (2013).Crossref, Medline, CAS, Google Scholar14. Lv Y, Xu C, Zhao X et al. Nanoplatform assembled from a CD44-targeted prodrug and smart liposomes for dual targeting of tumor microenvironment and cancer cells. ACS Nano 12(2), 1519–1536 (2018).Crossref, Medline, CAS, Google Scholar15. Cai R, Chen C. The crown and the scepter: roles of the protein corona in nanomedicine. Adv. Mater. 31(45), 1805740 (2019).Crossref, CAS, Google Scholar16. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat. Commun. 9(1), 1410 (2018).Crossref, Medline, Google Scholar17. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307(1), 93–102 (2006).Crossref, Medline, CAS, Google Scholar18. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33(9), 941–951 (2015).Crossref, Medline, CAS, Google Scholar19. Zou Y, Ito S, Yoshino F, Suzuki Y, Zhao L, Komatsu N. Polyglycerol grafting shields nanoparticles from protein corona formation to avoid macrophage uptake. ACS Nano 14(6), 7216–7226 (2020).Crossref, Medline, CAS, Google Scholar20. Rudnick SI, Lou J, Shaller CC et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 71(6), 2250–2259 (2011).Crossref, Medline, CAS, Google Scholar21. Chauhan VP, Stylianopoulos T, Martin JD et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7(6), 383–388 (2012).Crossref, Medline, CAS, Google Scholar22. Donahue ND, Acar H, Wilhelm S. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv. Drug Deliv. Rev. 143, 68–96 (2019).Crossref, Medline, CAS, Google Scholar23. Kinnear C, Moore TL, Rodriguez-Lorenzo L, Rothen-Rutishauser B, Petri-Fink A. Form follows function: nanoparticle shape and its implications for nanomedicine. Chem. Rev. 117(17), 11476–11521 (2017).Crossref, Medline, CAS, Google Scholar24. Behzadi S, Serpooshan V, Tao W et al. Cellular uptake of nanoparticles: journey inside the cell. Chem. Soc. Rev. 46(14), 4218–4244 (2017).Crossref, Medline, CAS, Google Scholar25. Kirpotin DB, Drummond DC, Shao Y et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66(13), 6732–6740 (2006).Crossref, Medline, CAS, Google Scholar26. Hühn D, Kantner K, Geidel C et al. Polymer-coated nanoparticles interacting with proteins and cells: focusing on the sign of the net charge. ACS Nano 7(4), 3253–3263 (2013).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 16, No. 17 Follow us on social media for the latest updates Metrics Downloaded 45 times History Received 13 March 2021 Accepted 29 March 2021 Published online 18 June 2021 Published in print July 2021 Information© 2021 Future Medicine LtdKeywordsendocytosismononuclear phagocytic systemnanomedicineprotein coronatumor penetrationAuthor contributionsL Liu: substantial contribution to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; and drafting the work or revising it critically for important intellectual content; H Dou: final approval of the version to be published; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.Financial & competing interests disclosureThe authors wish to gratefully acknowledge financial support from the National Natural Science Foundation of China (21871180), the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (SHDP201802), the ‘Shuguang Program’ supported by the Shanghai Municipal Education Commission (17SG12), the Science and Technology Commission of Shanghai Municipality (18520710300 and 17ZR1404100) and Biomedical Interdisciplinary Research Foundation of SJTU (YG2019QNB34). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download

Nanomedicine in Boron Neutron Capture Therapy for Cancer Treatment: Opportunities, Challenges and Future Perspectives

Obstacles Impeding the Development of Nanocarriers for Anticancer Drugs

Boron Neutron Capture Therapy in Clinical Application:Progress and Prospect

Localized nuclear reaction breaks boron drug capsules loaded with immune adjuvants for cancer immunotherapy

Catalytic Modulation of the Tumor Microenvironment Using Cascade Enzymes for Synergistic Boron Neutron Capture Therapy in the Treatment of Gliomas

Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies

The basis and advances in clinical application of boron neutron capture therapy

Stimuli-regulated cancer theranostics based on magnetic nanoparticles

Author Correction: Localized Nuclear Reaction Breaks Boron Drug Capsules Loaded with Immune Adjuvants for Cancer Immunotherapy

Boron neutron capture therapy of cancer: current status and future prospects

Importance of radiobiological studies for the advancement of boron neutron capture therapy (BNCT)

Boron nanoparticles in chemotherapy and radiotherapy: the synthesis, state-of-the-art, and prospects

Enhancing Cancer Therapy: Boron-Rich Polyboronate Ester Micelles for Synergistic Boron Neutron Capture Therapy and PD-1/PD-L1 Checkpoint Blockade

Boron Neutron Capture Therapy: Current Status and Challenges

A realistic appraisal of boron neutron capture therapy as a cancer treatment modality

Abstract 5051: Assessment of boron delivery peptides with angiopep-2 for boron neutron capture therapy

Theranostics in Boron Neutron Capture Therapy

Boron Neutron Capture Therapy: Clinical Application and Research Progress

Boron neutron capture therapy: Current status and future perspectives

Nonclinical pharmacodynamics of boron neutron capture therapy using direct intratumoral administration of a folate receptor targeting novel boron carrier

Ultrasound-based Nanomedicine for Molecular Imaging of Prostate Cancer: from Diagnostics to Theranostics